TS Gene Polymorphism Predicts Effect in Patients With Advanced Lung Cancer

• Status: Completed
• Trial end date: 2015-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The investigators performed a multicenter, open trial of using TS gene polymorphism to predict advanced lung adenocarcinoma effect to pemetrexed combined with cisplatin regiment as first-line treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hunan Province Tumor Hospital
• Treatments: Cisplatin; Pemetrexed

Criteria

Inclusion Criteria:

• histologic or cytologic proof of advanced lung adenocarcinoma

• primary treatment

• normal organ function

• Eastern Cooperative Oncology Group performance status 0 to 2

Exclusion Criteria:

• Symptomatic patients with brain metastases

• Major organ dysfunction and severe heart disease